These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 27381677)

  • 1. Navigation in bile acid chemical space: discovery of novel FXR and GPBAR1 ligands.
    Finamore C; Festa C; Renga B; Sepe V; Carino A; Masullo D; Biagioli M; Marchianò S; Capolupo A; Monti MC; Fiorucci S; Zampella A
    Sci Rep; 2016 Jul; 6():29320. PubMed ID: 27381677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation on bile acid receptor regulators. Discovery of cholanoic acid derivatives with dual G-protein coupled bile acid receptor 1 (GPBAR1) antagonistic and farnesoid X receptor (FXR) modulatory activity.
    Sepe V; Renga B; Festa C; Finamore C; Masullo D; Carino A; Cipriani S; Distrutti E; Fiorucci S; Zampella A
    Steroids; 2016 Jan; 105():59-67. PubMed ID: 26607331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemistry and Pharmacology of GPBAR1 and FXR Selective Agonists, Dual Agonists, and Antagonists.
    De Marino S; Festa C; Sepe V; Zampella A
    Handb Exp Pharmacol; 2019; 256():137-165. PubMed ID: 31201554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists.
    Sepe V; Festa C; Renga B; Carino A; Cipriani S; Finamore C; Masullo D; Del Gaudio F; Monti MC; Fiorucci S; Zampella A
    Sci Rep; 2016 Jan; 6():19008. PubMed ID: 26740187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introduction of Nonacidic Side Chains on 6-Ethylcholane Scaffolds in the Identification of Potent Bile Acid Receptor Agonists with Improved Pharmacokinetic Properties.
    Finamore C; Baronissi G; Marchianò S; Di Leva FS; Carino A; Monti MC; Limongelli V; Zampella A; Fiorucci S; Sepe V
    Molecules; 2019 Mar; 24(6):. PubMed ID: 30884797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of bile acid activated receptors hybrid molecules for the treatment of inflammatory and metabolic disorders.
    Fiorucci S; Sepe V; Biagioli M; Fiorillo B; Rapacciuolo P; Distrutti E; Zampella A
    Biochem Pharmacol; 2023 Oct; 216():115776. PubMed ID: 37659739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based drug design targeting the cell membrane receptor GPBAR1: exploiting the bile acid scaffold towards selective agonism.
    Di Leva FS; Festa C; Renga B; Sepe V; Novellino E; Fiorucci S; Zampella A; Limongelli V
    Sci Rep; 2015 Nov; 5():16605. PubMed ID: 26567894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of ((1,2,4-oxadiazol-5-yl)pyrrolidin-3-yl)ureidyl derivatives as selective non-steroidal agonists of the G-protein coupled bile acid receptor-1.
    Di Leva FS; Festa C; Carino A; De Marino S; Marchianò S; Di Marino D; Finamore C; Monti MC; Zampella A; Fiorucci S; Limongelli V
    Sci Rep; 2019 Feb; 9(1):2504. PubMed ID: 30792450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
    Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
    Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application.
    Sepe V; Distrutti E; Limongelli V; Fiorucci S; Zampella A
    Future Med Chem; 2015; 7(9):1109-35. PubMed ID: 26132522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Pharmacology of Bile Acids and Their Receptors.
    Fiorucci S; Distrutti E
    Handb Exp Pharmacol; 2019; 256():3-18. PubMed ID: 31201555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands.
    Festa C; Renga B; D'Amore C; Sepe V; Finamore C; De Marino S; Carino A; Cipriani S; Monti MC; Zampella A; Fiorucci S
    J Med Chem; 2014 Oct; 57(20):8477-95. PubMed ID: 25247751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural Insight into the Binding Mode of FXR and GPBAR1 Modulators.
    Di Leva FS; Di Marino D; Limongelli V
    Handb Exp Pharmacol; 2019; 256():111-136. PubMed ID: 31161298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR.
    Jadhav K; Xu Y; Xu Y; Li Y; Xu J; Zhu Y; Adorini L; Lee YK; Kasumov T; Yin L; Zhang Y
    Mol Metab; 2018 Mar; 9():131-140. PubMed ID: 29361497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SAR studies on FXR modulators led to the discovery of the first combined FXR antagonistic/TGR5 agonistic compound.
    Lamers C; Merk D; Gabler M; Flesch D; Kaiser A; Schubert-Zsilavecz M
    Future Med Chem; 2016; 8(2):133-48. PubMed ID: 26824277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist.
    Rizzo G; Passeri D; De Franco F; Ciaccioli G; Donadio L; Rizzo G; Orlandi S; Sadeghpour B; Wang XX; Jiang T; Levi M; Pruzanski M; Adorini L
    Mol Pharmacol; 2010 Oct; 78(4):617-30. PubMed ID: 20631053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the transsulfuration-H2S pathway by FXR and GPBAR1 ligands in the treatment of portal hypertension.
    Fiorucci S; Distrutti E
    Pharmacol Res; 2016 Sep; 111():749-756. PubMed ID: 27475883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of an Oleanane-Type Triterpene Hedragonic Acid as a Novel Farnesoid X Receptor Ligand with Liver Protective Effects and Anti-inflammatory Activity.
    Lu Y; Zheng W; Lin S; Guo F; Zhu Y; Wei Y; Liu X; Jin S; Jin L; Li Y
    Mol Pharmacol; 2018 Feb; 93(2):63-72. PubMed ID: 29162643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G-Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver Disease.
    Marchianò S; Biagioli M; Bordoni M; Morretta E; Di Giorgio C; Vellecco V; Roselli R; Bellini R; Massa C; Cari L; Urbani G; Ricci P; Monti MC; Giordano A; Brancaleone V; Bucci M; Zampella A; Distrutti E; Cieri E; Cirino G; Fiorucci S
    J Am Heart Assoc; 2023 Dec; 12(23):e031241. PubMed ID: 37996988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bile acid-activated receptors and the regulation of macrophages function in metabolic disorders.
    Fiorucci S; Baldoni M; Ricci P; Zampella A; Distrutti E; Biagioli M
    Curr Opin Pharmacol; 2020 Aug; 53():45-54. PubMed ID: 32480317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.